<DOC>
	<DOCNO>NCT02516605</DOCNO>
	<brief_summary>A multi-part study ass safety , tolerability efficacy LJN452 patient primary biliary cholangitis</brief_summary>
	<brief_title>A Multi-part , Double Blind Study Assess Safety , Tolerability Efficacy LJN452 PBC Patients</brief_title>
	<detailed_description />
	<mesh_term>Cholangitis</mesh_term>
	<criteria>Diagnosis PBC demonstrate presence ≥ 2 follow 3 diagnostic criterion : History Alkaline Phosphatase elevate upper limit normal least 6 month Positive antimitochondrial antibody ( AMA ) titer AMA negative low titer ( &lt; 1:80 ) PBC specific antibody ( anti GP210 and/or antiSP100 and/or antibody major M2 component ( PDCE2 , 2oxoglutaric acid dehydrogenase complex ) Previous liver biopsy consistent PBC At least 1 follow marker disease severity : ALP ≥ 1.67× upper limit normal ( ULN ) Total bilirubin &gt; ULN &lt; 2× ULN Subjects must weigh least 40 kg participate study , must body mass index ( BMI ) within range 18 40 kg/m^2 . BMI = Body weight ( kg ) / [ Height ( ) ] ^2 . Able communicate well investigator , understand comply requirement study . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 5 day follow end treatment . History presence concomitant liver diseases Clinically significant hepatic decompensation . History venous thromboembolism , TIA , intracranial hemorrhage , neoplasm , arteriovenous malformation , vasculitis , bleed disorder , coagulation disorder screen blood test indicate alter coagulability ( e.g . platelet count , aPTT , PTT TT test ) . History condition may cause increase ALP ( e.g. , Paget 's disease ) . Use investigational drug time enrollment , within 5 halflives enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Primary Biliary Cirrhosis , PBC</keyword>
	<keyword>Primary Biliary Cholangitis</keyword>
</DOC>